![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
619kB |
![[thumbnail of Supplemental Data]](https://edoc.mdc-berlin.de/id/eprint/23548/2/23548suppl.JPEG)  Preview |
Image (JPEG) (Supplemental Data)
36kB |
| Item Type: | Article |
|---|---|
| Title: | Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma |
| Creators Name: | Rieke, D.T., Schröder, S., Schafhausen, P., Blanc, E., Zuljan, E., von der Emde, B., Beule, D., Keller, U., Keilholz, U. and Klinghammer, K. |
| Abstract: | BACKGROUND AND PURPOSE: A subgroup of salivary duct carcinoma (SDC) harbor overexpression of the androgen receptor (AR), and co-occurring mutations in the HRAS- and PIK3CA-genes. The impact of genomic complexity on targeted treatment strategies in advanced cancer is unknown. MATERIALS AND METHODS: We analyzed molecular and clinical data from an institutional molecular tumor board (MTB) to identify AR+, HRAS/PIK3CA co-mutated SDC. Follow-up was performed within the MTB registrational study or retrospective chart review after approval by the local ethics committee. Response was assessed by the investigator. A systematic literature search was performed in MEDLINE to identify additional clinically annotated cases. RESULTS: 4 patients with AR+ HRAS/PIK3CA co-mutated SDC and clinical follow-up data were identified from the MTB. An additional 9 patients with clinical follow-up were identified from the literature. In addition to AR overexpression and HRAS and PIK3CA-alterations, PD-L1 expression and Tumor Mutational Burden > 10 Mutations per Megabase were identified as additional potentially targetable alterations. Among evaluable patients, androgen deprivation therapy (ADT) was initiated in 7 patients (1 Partial Response (PR), 2 Stable Disease (SD), 3 Progressive Disease (PD), 2 not evaluable), tipifarnib was initiated in 6 patients (1 PR, 4 SD, 1 PD). One patient each was treated with immune checkpoint inhibition (Mixed Response) and combination therapies of tipifarnib and ADT (SD) and alpelisib and ADT (PR). CONCLUSION: Available data further support comprehensive molecular profiling of SDC. Combination therapies, PI3K-inhibitors and immune therapy warrant further investigation, ideally in clinical trials. Future research should consider this rare subgroup of SDC. |
| Keywords: | Salivary Gland Cancer, Salivary Duct Carcinoma, Targeted Therapy, Precision Oncology, Molecular Tumor Board, Head and Neck Cancer |
| Source: | Frontiers in Oncology |
| ISSN: | 2234-943X |
| Publisher: | Frontiers Media SA |
| Volume: | 13 |
| Page Range: | 1107134 |
| Date: | 2023 |
| Official Publication: | https://doi.org/10.3389/fonc.2023.1107134 |
Repository Staff Only: item control page
